CAMBRIDGE, Mass.--(BUSINESS WIRE)--Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, announced today that it will receive a milestone payment from its collaborator Ophthotech Corp. The milestone payment has been triggered by Ophthotech’s enrollment of the first volunteer in a Phase 1 study of E10030, an anti-platelet derived growth factor (PDGF) aptamer which is being developed for age related macular degeneration (AMD). The Phase 1 trial is testing the safety and tolerability of E10030 in combination with an anti-vascular endothelial growth factor (VEGF) agent. This trial will enroll up to a maximum of 36 patients.
